No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 601,514 | 577,426 | 691,530 | 755,821 | 762,302 | 807,200 | 811,638 | N/A | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 14,004 | 15,831 | 26,488 | 23,008 | 23,221 | 25,309 | 30,978 | N/A | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Kaneka Corporation, established in Tokyo, Japan, in 1949, operates internationally as a diversified manufacturer providing a wide array of advanced materials and specialized products. Its core chemical business includes the production and global distribution of various polyvinyl chloride (PVC) formulations, such as crosslinked, paste, and chlorinated PVC, alongside acryl grafted-vinyl chloride copolymers. The company also supplies critical additives like impact modifiers, processing aids, specialty additives, and tougheners for thermosetting resins. Furthermore, their portfolio features advanced polymers including silyl-terminated polyether, acrylic silicon, terminally reactive liquid acrylic, biodegradable polymers, and engineering resins designed for injection molding, in addition to zero birefringence materials, acrylic films, and isobutylene-based thermoplastic elastomers. Beyond chemicals, Kaneka manufactures specialized foams and films, encompassing polypropylene and Kanelite foams, extruded polystyrene insulation, polyimide films, and transparent films for optical applications. Their material science expertise extends to high thermal conductive graphite sheets, multi-layer insulation, transparent conductive films, and transparent resins engineered for exceptional heat and light resistance. In the energy and innovative products sector, Kaneka offers photovoltaic power generation systems suitable for residential, public, and industrial installations. Other cutting-edge developments include eco-friendly fur, flame-retardant materials, hair accessories, novel materials, organic EL lighting panels, and biosurfactants. Their life sciences division delivers a comprehensive range of medical and pharmaceutical offerings, which include intervention and blood purification systems, gastroenterology intervention tools, diagnostic testing equipment, regenerative medicine and cell therapy solutions, and genetic diagnostics. Additionally, they provide low molecular pharmaceutical raw materials, affinity chromatography resins for monoclonal antibody purification, biopharmaceuticals, transdermal medicines, and innovative shock-absorbing innerwear. Lastly, Kaneka is a significant player in the food and nutrition industry. Their extensive product line features dairy products, margarines, fats and oils, whipping creams, fillings, baking essentials (baker's yeast, dough improvers), processed fruits, butter, shortening, cacao butter alternatives, various creams, frozen dough, spices, and antifreeze materials. They also supply pharmaceutical and supplemental nutrition solutions, such as coenzyme Q10, lactic-acid bacteria, and functional foodstuffs, alongside agricultural fertilizers.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Kaneka Corporation (4118.T)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Kaneka Corporation, established in Tokyo, Japan, in 1949, operates internationally as a diversified manufacturer providing a wide array of advanced materials and specialized products. Its core chemical business includes the production and global distribution of various polyvinyl chloride (PVC) formulations, such as crosslinked, paste, and chlorinated PVC, alongside acryl grafted-vinyl chloride copolymers. The company also supplies critical additives like impact modifiers, processing aids, specialty additives, and tougheners for thermosetting resins. Furthermore, their portfolio features advanced polymers including silyl-terminated polyether, acrylic silicon, terminally reactive liquid acrylic, biodegradable polymers, and engineering resins designed for injection molding, in addition to zero birefringence materials, acrylic films, and isobutylene-based thermoplastic elastomers. Beyond chemicals, Kaneka manufactures specialized foams and films, encompassing polypropylene and Kanelite foams, extruded polystyrene insulation, polyimide films, and transparent films for optical applications. Their material science expertise extends to high thermal conductive graphite sheets, multi-layer insulation, transparent conductive films, and transparent resins engineered for exceptional heat and light resistance. In the energy and innovative products sector, Kaneka offers photovoltaic power generation systems suitable for residential, public, and industrial installations. Other cutting-edge developments include eco-friendly fur, flame-retardant materials, hair accessories, novel materials, organic EL lighting panels, and biosurfactants. Their life sciences division delivers a comprehensive range of medical and pharmaceutical offerings, which include intervention and blood purification systems, gastroenterology intervention tools, diagnostic testing equipment, regenerative medicine and cell therapy solutions, and genetic diagnostics. Additionally, they provide low molecular pharmaceutical raw materials, affinity chromatography resins for monoclonal antibody purification, biopharmaceuticals, transdermal medicines, and innovative shock-absorbing innerwear. Lastly, Kaneka is a significant player in the food and nutrition industry. Their extensive product line features dairy products, margarines, fats and oils, whipping creams, fillings, baking essentials (baker's yeast, dough improvers), processed fruits, butter, shortening, cacao butter alternatives, various creams, frozen dough, spices, and antifreeze materials. They also supply pharmaceutical and supplemental nutrition solutions, such as coenzyme Q10, lactic-acid bacteria, and functional foodstuffs, alongside agricultural fertilizers.
